Open Access

Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Event: ESC Congress 2021 - The Digital Experience
Topic: Risk Factors and Prevention
Session type: Satellite Symposium
Sponsored by PACE-CME
Date: 27 August 2021
Time: 13:00 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

Speaker: Professor K. Ray (London, GB)
Thumbnail

The urgency to treat LDL-c post MI: The role of PCSK9 mAbs in reaching goals.

Speaker: Professor D. Connolly (Birmingham, GB)
Thumbnail

Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute.

Speaker: Doctor C. Ballantyne (Houston, US)
Thumbnail

Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?

Speaker: Professor J. Kastelein (Amsterdam, NL)
Thumbnail

4 speakers from this session

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
3 followers

Professor Derek Leslie Connolly

City Hospital, Birmingham (United Kingdom of Great Britain & Northern Ireland)
12 presentations
0 follower

Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)
16 presentations
1 follower

Professor John Kastelein

Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))
21 presentations
1 follower

Related content

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Current controversies in antithrombotic therapy

3 December 2021

ESC Premium Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk